Uterine fibroid
Conditions
Sponsors
Takeda Pharmaceutical Company Limited
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: Inclusion Criteria for Entering the Screening (at VISIT 1) 1. In the opinion of the investigator or subinvestigator, the participant is capable of understanding and complying with protocol requirements. 2. The participant signs and dates a written, informed consent form prior to the initiation of any study procedures. 3. Prior to VISIT 1, the participant has a diagnosis of uterine fibroids confirmed by transvaginal ultrasound, abdominal ultrasound, magnetic resonance imaging (MRI), computed tomography (CT), or laparoscopy, and has never received surgical treatment for the myoma (measurable noncalcified myoma with a longest diameter of >=3 cm). 4. The participant is a premenopausal Japanese woman. 5. The participant is aged 20 years or older on the day of signing and dating the informed consent form. 6. The participant has 1 or more measurable noncalcified myomas with a longest diameter of >=3 cm confirmed by transvaginal ultrasound. 7. The participant has experienced 1 or more regular menstrual cycles (25 to 38 days) immediately prior to VISIT 1 and that should include menstrual bleeding of at least 3 consecutive days. 8. The participant who is sexually active with a nonsterilized male partner agrees to use routinely adequate contraception from signing of informed consent throughout the duration of the study. Inclusion Criteria for Entering the Run-in (at VISIT 2) 9. The participant has experienced regular menstrual cycles (25 to 38 days) immediately prior to VISIT 2 that should include menstrual bleeding of at least 3 consecutive days (at least 2 regular menstruation cycles to be confirmed by Inclusion criteria #7 and #9). Inclusion Criteria for Entering the Treatment (at VISIT 3) 10. The participant has 1 or more measurable noncalcified myomas, with a longest diameter of >=3 cm confirmed by transvaginal ultrasound (the same myoma should be measured as in Inclusion criterion #6). 11. The participant has a maximum Numerical Rating Scale (NRS) score of >=4 in 1 menstrual cycle just before VISIT 3. 12. The participant has pain symptoms associated with uterine fibroids of at least 2 days in 1 menstrual cycle just before VISIT 3. 13. The participant has experienced regular menstrual cycles (25 to 38 days) after VISIT 1 that should include menstrual bleeding of at least 3 consecutive days (at least 3 regular menstruation cycles to be confirmed by Inclusion criteria #7, #9 and #13).
Exclusion criteria
Exclusion criteria: 1. The participant has received any investigational compound within 24 weeks prior to the start of the administration of the study medication for the day of first menstruation after VISIT 1. 2. The participant has received TAK-385 (including placebo) in a previous clinical study. 3. The participant is an immediate family member, study site employee, or is in a dependant relationship with a study site employee who is involved in conduct of this study (eg, spouse, parent, child, sibling) or may consent under duress. 4. The participant has lower abdominal pain due to irritable bowel syndrome or severe interstitial cystitis. 5. The participant has a current history of thyroid gland disorder with irregular menstruation, or has a potential for irregular menstruation due to thyroid gland disorder, as determined by the investigator or subinvestigator. 6. The participant has a previous or current history of pelvic inflammatory disease within the 8 weeks prior to VISIT 1. 7. The participant has a positive Pap smear test result conducted within the 1 year prior to VISIT 1 (if there are no previous test results, those who were judged positive in the test conducted before VISIT 2). 8. The participant has a history of panhysterectomy or bilateral oophorectomy. 9. The participant has had markedly abnormal uterine bleeding or anovulatory bleeding, as determined by the investigator or subinvestigator. 10. The participant has a malignant tumor or a history of a malignant tumor within the 5 years prior to VISIT 1. 11. The participant has been treated with selective estrogen receptor modulators (SERMs) (excluding drugs for external use and dietary supplements) within the 4 weeks prior to VISIT 2. 12. The participant has been treated with any of the following drugs within the 8 weeks prior to VISIT 2: oral contraceptive or sex hormone preparations (norethindrone, norethisterone, medroxyprogesterone, estrogen, or other progestins), and within the 16 weeks prior to VISIT 2: gonadotropin-releasing hormone (GnRH) analogues, dienogest, danazol, or aromatase inhibitors (for 1- and 3-month sustained-release preparations, within the 20 and 28 weeks prior to VISIT 2, respectively). 13. The participant has a previous or current history of severe hypersensitivity or severe allergies to drugs. 14. The participant has nondiagnosable abnormal genital bleeding. 15. Female participant who is pregnant, lactating, or intending to become pregnant or to donate ova prior to signing of informed consent, during the study period, or within 1 month after the end of the study. 16. The participant has clinically significant cardiovascular disease (eg, myocardial infarction or unstable angina pectoris within the 24 weeks prior to VISIT 1) or uncontrollable hypertension (eg, resting systolic blood pressure >=180 mmHg or diastolic blood pressure >=110 mmHg at Screening and Run-in). 17. The participant is inappropriate for participation in this study based on standard 12-lead electrocardiogram (ECG) findings, as determined by the investigator or subinvestigator. 18. The participant has active liver disease or jaundice, or with alanine aminotransferase (ALT), aspartate aminotransferase (AST), or bilirubin (total bilirubin) >1.5 times the upper limit of normal (ULN) in the clinical laboratory tests at VISIT 1 and 2. 19. The participant has previous or current history of diseases considered to be inappropriate for participation in this study, including severe hepatic impairment, jaundice, r
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Efficacy: Proportion of subjects with a maximum NRS score of 1 or less Primary timeframe: Timeframe; During the 28 days before Week 12 | — |
Secondary
| Measure | Time frame |
|---|---|
| Efficacy: Proportion of subjects with a maximum NRS score of 0, Mean NRS score, Number of days without pain symptoms (NRS = 0), Safety: Adverse events, vital signs, weight, standard 12-lead ECG, clinical laboratory tests Secondary timeframe: Timeframe; Efficacy: During the 28 days before Week 12, Safety: Up to 28 days from Week 12 | — |
Outcome results
None listed